Multidisciplinary, whole-process management of a patient with recurrent serous borderline ovarian tumor from embryo cryopreservation before re-fertility-sparing surgery to successful delivery: a case report
- PMID: 40781609
- PMCID: PMC12335055
- DOI: 10.1186/s12884-025-07918-0
Multidisciplinary, whole-process management of a patient with recurrent serous borderline ovarian tumor from embryo cryopreservation before re-fertility-sparing surgery to successful delivery: a case report
Abstract
Background: For patients with recurrent serous borderline ovarian tumors (BOT) who have undergone unilateral salpingo-oophorectomy, there is a risk of reduced or even lost ovarian reserve after the second surgery; therefore, fertility preservation (FP) prior to re-operation in patients of childbearing age is challenging, and has attracted increasing attention. Here, we discuss the multidisciplinary whole-process management of a patient with recurrent serous BOT, from embryo cryopreservation (EC) before re-fertility-sparing surgery (re-FSS) to successful delivery.
Case presentation: We describe the treatment of a 28-year-old married, nulliparous female with recurrent serous BOT who requested FP. The patient underwent right salpingo-oophorectomy in July 2020 for serous BOT. In March 2023, B-ultrasound indicated BOT recurrence, and she underwent a second operation. After a multidisciplinary discussion and information on the risks, the patient strongly requested EC. We used letrozole (LE) combined with an antagonist for ovarian stimulation; 16 eggs were obtained, 15 eggs were MII, four embryos on the 3rd day and one blastocyst was formed and cryopreserved. One month later, laparoscopic cystectomy was performed, and pathological examination revealed serous BOT. Three months after the operation, resuscitation and transplantation of one blastocyst did not result in pregnancy through the natural cycle (NC), followed by resuscitation and transfer of two embryos on day 3 through hormone replacement therapy (HRT), which resulted in a successful pregnancy and live healthy male birth. No recurrence was reported at 19 months after re-FSS.
Conclusions: This case highlights the key points of comprehensive multidisciplinary management from the discovery of BOT recurrence, multidisciplinary team (MDT) consultation, ovarian stimulation (OS), egg retrieval, EC, re-FSS, frozen embryo transfer (FET), to delivery. Re-FSS is safe and effective for patients with recurrent serous BOT and strong fertility requirements, and EC before re-FSS is feasible.
Keywords: Borderline ovarian tumor (BOT); Case report; Embryo cryopreservation (EC); Multidisciplinary team (MDT); Re-fertility-sparing surgery (re-FSS).
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: This study was approved by the Medical Ethics Committee of First People’s Hospital of Yunnan Province (number: 2024-GN013). All the patients agreed to participate in the study. Consent for publication: Written informed consent for publication was obtained from the patient. The hospital ethics committee approved the publication of this manuscript. Competing interests: The authors declare no competing interests.
Figures



Similar articles
-
Interventions for fertility preservation in women with cancer undergoing chemotherapy.Cochrane Database Syst Rev. 2025 Jun 19;6(6):CD012891. doi: 10.1002/14651858.CD012891.pub2. Cochrane Database Syst Rev. 2025. PMID: 40536056 Review.
-
Single-cell analysis comparing early-stage oocytes from fresh and slow-frozen/thawed human ovarian cortex reveals minimal impact of cryopreservation on the oocyte transcriptome.Hum Reprod. 2025 Apr 1;40(4):683-694. doi: 10.1093/humrep/deaf009. Hum Reprod. 2025. PMID: 39919251
-
Hematologic cancers in women: from fertility preservation to post-cancer fertility outcomes.Hum Reprod. 2025 Jul 1;40(7):1315-1324. doi: 10.1093/humrep/deaf071. Hum Reprod. 2025. PMID: 40302200
-
Fertility Following Fertility-Sparing Surgery for Borderline Ovarian Tumors.Semin Reprod Med. 2025 Jul 23. doi: 10.1055/s-0045-1810420. Online ahead of print. Semin Reprod Med. 2025. PMID: 40701565
-
Oocyte, embryo and blastocyst cryopreservation in ART: systematic review and meta-analysis comparing slow-freezing versus vitrification to produce evidence for the development of global guidance.Hum Reprod Update. 2017 Mar 1;23(2):139-155. doi: 10.1093/humupd/dmw038. Hum Reprod Update. 2017. PMID: 27827818 Free PMC article.
References
-
- Gracia M, Alonso-Espías M, Zapardiel I. Current limits of conservative treatment in ovarian cancer. Curr Opin Oncol. 2023;35:389–93. - PubMed
-
- Morice P, Scambia G, Abu-Rustum NR, Acien M, Arena A, Brucker S, Cheong Y, Collinet P, Fanfani F, Filippi F, Eriksson AGZ, Gouy S, Harter P, Matias-Guiu X, Pados G, Pakiz M, Querleu D, Rodolakis A, Rousset-Jablonski C, Stepanyan A, Testa AC, Macklon KT, Tsolakidis D, De Vos M, Planchamp F, Grynberg M. Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGE. Lancet Oncol. 2024;25:e602–10. - PubMed
Publication types
MeSH terms
Grants and funding
- XDYC-QNRC-2023-0443/Science and Technology plan project of the First People's Hospital of Yunnan Province
- KUST-KH2023021Y/Kunming University of Science and Technology Medical Joint Project
- 82260301/the National Natural Science Foundation of China Regional Science Foundation Project
- 202405AC350060/Yunnan Province High-level Scientific and Technological Talents and Innovation Team Selection Special-Young and Middle-aged Academic and Technical Leaders Reserve Talent Project
LinkOut - more resources
Full Text Sources
Medical